Clinical Trials

ADOPT – Lung

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab, and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. (ADOPT-lung)

Recruitment target:

((23 randomised))

Status:

In Start-up

(Status: In start-up (anticipated opening Q4 2024))

Summary:

The ADOPT-Lung study will examine disease free status (DFS) following 12 months of adjuvant durvalumab in addition to neoadjuvant chemotherapy and durvalumab in NSCLC patients who do not achieve a complete pathological response following surgery. ‘Operable’ patients will be given 3-4 cycles of neoadjuvant durvalumab and chemotherapy every 3 weeks, and provided the tumour is satisfactorily removed by surgery (R0 or R1), the patients will be randomised to 12 months of durvalumab given every 4 weeks, or observation. Participants will have CT scans every 12 weeks in the first year, and every 6 months in years 2 and 3. Blood will be collected at the scan visit to measure correlation of DFS with ctDNA clearance.

Clinical trial design:

Phase III randomised open-label study

Indication:

‘Operable’ Stage IIB-IIIB NSCLC with absence of EGFR mutation or ALK translocation

Intervention:

12 months of durvalumab (immunotherapy) every 4 weeks after surgery

More information:

For clinicians

Contact: TBD

More Clinical Trials

In Start-up:

In Start-up

21/013 VitAL

Radiation therapy (RT) is indicated for 77% of lung cancer patients. A common adverse event, affecting at least 20% of patients, is radiation-induced lung injury. To minimise radiation-induced lung injury, Professor Keall’s team has invented and pioneered ventilation imaging based on computed tomography (CT) which has been developed into a medical device (CIA). This medical device uses CT scans routinely acquired for planning RT to compute a CT ventilation map showing high functioning and low functioning lung regions. VitAL aims to investigate whether the use of CIA can be used to direct radiation away from the healthy, high functioning regions towards the low functioning regions, thereby reducing toxicity and improving the patient’s quality of life.

Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

TOGA

Quicklinks

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.